Today: 3 July 2026
Warby Parker stock (WRBY) in focus after co-CEOs’ share sales hit SEC filings
12 January 2026
1 min read

Warby Parker stock (WRBY) in focus after co-CEOs’ share sales hit SEC filings

NEW YORK, Jan 11, 2026, 19:52 EST — The market has closed.

  • Warby Parker’s co-CEOs revealed they sold shares through pre-arranged trading plans.
  • WRBY closed Friday at $28.30, wrapping up a solid start to 2026.
  • Investors are now eyeing any additional insider filings and when the quarterly results will drop.

Warby Parker’s co-chief executives reported stock sales in filings signed late Friday, giving investors new data ahead of Monday’s open.

The eyewear company’s shares closed Friday at $28.30, edging up 0.07% for the day and roughly 25% above their first closing price of 2026. Such gains often draw extra scrutiny to insider transactions, even if they’re standard.

The focus now shifts from selling to the setup. When U.S. markets reopen after the weekend, WRBY remains on a short-lived rally. Traders will soon find out if momentum buyers push forward or pull back.

Both co-CEOs tapped into Rule 10b5-1 plans—preset trading schemes that allow insiders to arrange sales ahead of time. These plans aim to minimize the chance that their trades are linked to non-public information.

Co-CEO David Abraham Gilboa swapped Class B shares for Class A shares and offloaded 75,000 Class A shares on Jan. 7, fetching an average price of $27.09. He sold an additional 19,906 shares on Jan. 9 at an average price of $29.09. After these transactions, he still directly holds 37,247 Class A shares, according to the filing.

Co-CEO Neil Harris Blumenthal converted Class B shares and offloaded 50,000 Class A shares on Jan. 7, fetching an average price of $27.08 each. After the sale, he holds 37,119 Class A shares directly, his filing shows.

The conversions are significant since Warby Parker issues several share classes. The filings note that Class B shares convert one-for-one into Class A, with automatic triggers linked to transfers and other events.

Investors aren’t just focused on the filings—they’re betting on a bigger narrative for Warby Parker: its move into smart eyewear. Last month, the company announced a collaboration with Alphabet’s Google to create “lightweight and AI-enabled” glasses, aiming for a first product launch in 2026. Reuters

That context makes any insider signal particularly noteworthy right now. While a planned sale isn’t the same as an impulsive sell-off, it can still spark fresh “now what?” questions after a rapid price shift.

There’s a risk, too. If excitement around wearable AI hardware fades — a space where Meta and Apple already hold early advantages — Warby Parker might end up with a costly development plan but limited short-term gains, leaving its core retail operation to shoulder the financial burden.

Monday’s session kicks off with a focus on volume and whether the stock sustains momentum after the latest disclosures. Additional Form 4 filings could extend the insider trading story. Investors are also waiting for the company to announce its next quarterly earnings date; Zacks projects Warby Parker will report on Feb. 26.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Raffles Medical Group (SGX:BSL) jumps after AI brain imaging partnership, valuation gap in focus
    July 3, 2026, 12:51 PM EDT. Raffles Medical Group (SGX:BSL) moved after a new partnership with Neurophet to provide AI software for brain MRI scans tied to neurodegenerative diseases. Shares traded at SGD0.93. The one-year shareholder return sits at -5.04%; year-to-date, the stock is down 8.82%. The P/E ratio is 24.3 times, which is below the peer group average of 29.4 but higher than the Asian healthcare industry's 19.9 and just above a calculated fair P/E of 23.8. A DCF model puts value 38.9% higher at SGD1.52, pointing to possible undervaluation. The market is weighing those potential gains against earnings risks and regulatory uncertainty in Singapore and Greater China.
UiPath stock: CEO share sale filing puts PATH in focus ahead of a busy week
Previous Story

UiPath stock: CEO share sale filing puts PATH in focus ahead of a busy week

National Grid plc stock drops today as markets wobble; dividend clock ticks on NG.L
Next Story

National Grid plc stock drops today as markets wobble; dividend clock ticks on NG.L

Go toTop